Persistence of high EBNA-1 titers across longitudinal samples was characteristic of MS, whereas MOGAD and NMOSD generally exhibited titer attenuation during follow-up. High-level EBNA-1 positivity in ...

A new study examined organizational differences of whole-brain networks between MS and NMOSD in a prospective cohort of patients with CNS demyelinating disease. All 144 study participants, including ...

SAN DIEGO — Treatment with daratumumab, a monoclonal antibody approved to treat multiple myeloma, was associated with a significant decrease in relapse risk in patients with aquaporin-4 immunoglobulin ...

Please provide your email address to receive an email when new articles are posted on . Ultomiris is a C5 complement inhibitor for neuromyelitis optica spectrum disorder. Trial patients did not ...

A systematic review identified 15 studies, enabling a meta-analysis of 443 NMOSD patients with 639 pregnancies. Rates of pregnancy-related NMOSD relapses were highest during the first 3 months ...

Transverse myelitis in a patient with neuromyelitis optica spectrum disorder Three agents were recently FDA approved for NMOSD in adults who are AQP4 antibody positive: eculizumab, inebilizumab-cdon, ...

Researchers in the Department of Neurology at Tohoku University, which is led by professor Masashi Aoki, have developed a classification scheme for neuromyelitis optica spectrum disorder, a rare ...

Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disorder that mostly affects your eyes and spinal cord. Your immune system attacks a specific protein, called aquaporin-4 (AQP4). The ...

(RTTNews) - The European Commission has approved Horizon Therapeutics plc's (HZNP) Uplizna or inebilizumab for the treatment of adults with Neuromyelitis Optica Spectrum Disorder. Uplizna is indicated ...

Please provide your email address to receive an email when new articles are posted on . In a company release, Horizon Therapeutics announced results from a phase 2/3 trial demonstrating that its ...

TOKYO--(BUSINESS WIRE)--Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that Roche has received notification that the European Medicines Agency’s (EMA) Committee for Medicinal Products ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. Dr ...